NCT00278161 · OUTCOME

Event-free Survival

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma · Source last updated 2018-11-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: 5 years

What was measured

Percentage of participants alive without disease relapse.

Analysis population: Participants were split into two populations for this outcome only: mantle-cell lymphoma and other low-grade B-cell tumors.

Groups in this outcome

R-HiCy

Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support. Pegfilgrastim: 6 mg SQ 24-48 hours after last dose of cyclophosphamide. Rituximab: 375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52. Cyclophosphamide: 50 mg/kg/day on Days 15, 16, 17, and 18.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
R-HiCy	81

Reported measurements

Mantle-cell lymphoma

Analysis denominator · Participants

Group	Source count
R-HiCy	39

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
R-HiCy	39	Not reported	Not reported	Not reported	Not reported

Other low-grade B-cell tumors

Analysis denominator · Participants

Group	Source count
R-HiCy	42

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
R-HiCy	40	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
39
denoms
counts
group Id
OG000
value
39
units
Participants
title
Mantle-cell lymphoma
categories
measurements
group Id
OG000
value
40
denoms
counts
group Id
OG000
value
42
units
Participants
title
Other low-grade B-cell tumors

denoms

counts
group Id
OG000
value
81
units
Participants

description

Percentage of participants alive without disease relapse.

groups

description
Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support. Pegfilgrastim: 6 mg SQ 24-48 hours after last dose of cyclophosphamide. Rituximab: 375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52. Cyclophosphamide: 50 mg/kg/day on Days 15, 16, 17, and 18.
id
OG000
title
R-HiCy

param Type

NUMBER

population Description

Participants were split into two populations for this outcome only: mantle-cell lymphoma and other low-grade B-cell tumors.

reporting Status

POSTED

time Frame

5 years

title

Event-free Survival

type

PRIMARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice